Last updated: August 31, 2026
On Friday, August 28, 2026, five scheduled life sciences catalysts arrived as promised: FDA approvals for Takeda’s Mimrylo and Roivant’s Lisraya, a cardiovascular label for Lilly’s Mounjaro, and full data for Cytokinetics’ ACACIA-HCM and AstraZeneca and Ionis’ CARDIO-TTRansform at ESC. All five sponsors closed lower on the day.
This page documents each delivered catalyst from the weekend of August 28 to 30, 2026, with the primary source figures, the label or endpoint language that differed from the headline, the exchange closes, and the rest of the weekend’s verified record: BioNTech’s colorectal vaccine halt, the Boston Scientific manufacturing disclosure, BioXcel’s Chapter 11 sale to Teva, Genentech’s DualityBio license, the Fifth Circuit’s PhRMA ruling, and the 2026 to 2027 COVID-19 vaccine approvals.
Which five catalysts were delivered on August 28, 2026 and how did the stocks close?
Five sponsors received exactly the event they had scheduled on Friday, August 28, 2026, and every one of them finished the session below Thursday’s close. The moves ranged from Lilly’s 0.1 percent to Roivant’s 7.6 percent. All figures below are official exchange closes; no cause is assigned beyond the shared date.
| Sponsor (ticker) | Event delivered Aug 28 | What the headline said | What the primary document said | Aug 27 close | Aug 28 close | Move |
|---|---|---|---|---|---|---|
| Roivant / Priovant (ROIV) | FDA approval of Lisraya (brepocitinib) in dermatomyositis, announced Aug 27 after the close | First targeted oral therapy for dermatomyositis | Boxed warning for serious infections, mortality, malignancy, MACE and thrombosis; no effect size disclosed for the primary endpoint | $37.58 | $34.71 | −7.6% |
| Protagonist (PTGX), partner Takeda (TAK) | FDA approval of Mimrylo (rusfertide) in polycythemia vera; $275M triggered to Protagonist | First in class hepcidin mimetic, 76.9% response | Endpoint is freedom from phlebotomy in weeks 20 to 32; injection site reactions in 56% of patients; price not disclosed | $149.50 | $144.33 | −3.5% (TAK flat at $18.03) |
| Eli Lilly (LLY) | FDA approval of Mounjaro (tirzepatide) to lower MACE risk in type 2 diabetes | 8% lower rate of CV death, heart attack or stroke vs Trulicity | Hazard ratio 0.92 (95.3% CI 0.83 to 1.01); non inferiority demonstrated; superiority not established | $1,176.10 | $1,174.61 | −0.1% |
| Cytokinetics (CYTK) | ACACIA-HCM full results at ESC Hot Line plus NEJM publication | First ever positive trial in non obstructive HCM | KCCQ difference 3.0 points; peak VO2 difference 0.67 mL/kg/min; LVEF below 50% in 10.5% vs 0.8%; every number already disclosed May 5 | $77.90 | $72.09 | −7.5% |
| Ionis (IONS) and AstraZeneca (AZN) | CARDIO-TTRansform full results at ESC Hot Line | Miss confirmed (topline July 9) | Rate ratio 0.89 (95% CI 0.73 to 1.09, p=0.277); no added benefit in the 57% on background stabilizer; nominal benefit only as monotherapy | $62.43 / $164.52 | $61.05 / $162.70 | −2.2% / −1.1% |
Sources for the closes are the consolidated exchange closes for August 27 and 28, 2026. For each approval the primary documents are the FDA press announcements and the sponsors’ releases; for the two ESC trials, the sponsor releases, the ESC press office and the NEJM publications.
What did the FDA approve Mimrylo (rusfertide) for and what did the VERIFY trial show?
The FDA approved Takeda’s Mimrylo (rusfertide) on August 28, 2026 for erythrocytosis in adults with polycythemia vera, the first hepcidin mimetic to reach the market. In the Phase 3 VERIFY trial, 76.9 percent of patients on Mimrylo needed no phlebotomy in weeks 20 to 32, against 32.9 percent on placebo. The review was a priority review with a target action date the companies had guided to the third quarter of 2026, so the decision landed inside its window.
| VERIFY element | Detail (FDA and Takeda releases, Aug 28, 2026) |
|---|---|
| Design | Multicenter, randomized, double blind, placebo controlled Phase 3; 293 adults with PV requiring frequent phlebotomy despite standard care; 32 week primary period, 52 weeks of tolerability data |
| Dosing | 19 mg subcutaneous once weekly to start, self injected, titrated to keep hematocrit below 45 percent |
| Primary endpoint | No phlebotomy required in weeks 20 to 32: 76.9% Mimrylo vs 32.9% placebo |
| Patient reported measures | PROMIS Fatigue Short Form 8a and MFSAF version 4.0 (Takeda; no effect sizes in the release) |
| Safety | Injection site reactions 56%, anemia 16% (Takeda); complete blood count every two to four weeks; warnings for thrombocytosis and embryo fetal toxicity |
| Population | Approximately 90,000 US patients with PV; 78% experience uncontrolled hematocrit on current care (Takeda) |
| Price and launch date | Not disclosed in either release |
Protagonist Therapeutics, which discovered rusfertide, said the approval triggers $275 million in payments: a $200 million second installment of the US opt out payment it elected in April 2026 plus a $75 million approval milestone. Protagonist keeps tiered worldwide royalties of 14 to 29 percent, which it describes as roughly 21 percent on a weighted basis at $1.5 billion of annual sales, plus up to $875 million of further milestones. Protagonist reported $849.5 million of cash and investments at June 30, 2026, before the $275 million. The stock closed at $144.33 on August 28, down 3.5 percent; Takeda’s US shares closed unchanged at $18.03.
What did the FDA approve Lisraya (brepocitinib) for and what is in the label?
The FDA approved Lisraya (brepocitinib), from Roivant subsidiary Priovant Therapeutics, on August 27, 2026 as the first oral and first targeted therapy for dermatomyositis in adults. It is a JAK1 and TYK2 inhibitor dosed at 30 mg once daily, approved with orphan drug designation under priority review, and it carries the JAK class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.
| VALOR element | Detail (FDA and Priovant releases, Aug 27, 2026) |
|---|---|
| Design | Phase 3, randomized, double blind, placebo controlled; 241 adults at 90 sites; 1:1:1 to brepocitinib 30 mg, 15 mg or placebo; 52 week treatment period |
| Primary endpoint | Myositis Total Improvement Score at week 52; the 30 mg arm achieved a higher mean TIS than placebo (FDA). Neither release states the mean difference or a p value |
| Steroid sparing | 55% of Lisraya patients achieved at least moderate improvement with minimal or no steroid use vs 30% on placebo; among patients on at least 7.5 mg per day at baseline, 62% tapered to 2.5 mg or less vs 38%, and 45% discontinued steroids vs 29% (Priovant) |
| Discontinuations | 6% on Lisraya 30 mg vs 11% on placebo (FDA) |
| Most common adverse reactions | Upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea |
| Boxed warning | Serious infections, mortality, malignancy, MACE, thrombosis |
| Availability and price | Available immediately through specialty pharmacies; price not disclosed; copay program to $0 for eligible patients |
| Follow on programs | Phase 3 in non infectious uveitis and cutaneous sarcoidosis; Phase 2b/3 in lichen planopilaris |
Priovant’s March 3, 2026 acceptance release had guided to a third quarter target action date and a US launch by the end of September, so this was a queue review that delivered inside its window with a month to spare. Roivant closed at $34.71 on August 28, down 7.6 percent from $37.58.
What does Mounjaro’s new cardiovascular indication actually say?
The FDA approved Mounjaro (tirzepatide) on August 28, 2026 to lower the risk of major adverse cardiovascular events, meaning cardiovascular death, non fatal heart attack or non fatal stroke, in adults with type 2 diabetes at high risk for those events. It is the first dual GIP and GLP-1 receptor agonist with a cardiovascular indication. The label rests on non inferiority to dulaglutide; Lilly’s release states that superiority was not established.
| SURPASS-CVOT element | Detail (Lilly release, Aug 28, 2026) |
|---|---|
| Design | Event driven, randomized, double blind Phase 3; 13,299 adults with type 2 diabetes and established cardiovascular disease randomized 1:1; 640 sites in 30 countries; median follow up 210.1 weeks |
| Comparator | Trulicity (dulaglutide) 1.5 mg, a GLP-1 receptor agonist with an established cardiovascular benefit |
| Primary result | MACE-3 hazard ratio 0.92 (95.3% CI 0.83 to 1.01), an 8% lower rate; non inferiority demonstrated, superiority not established |
| Safety | Gastrointestinal events most common, generally mild to moderate, concentrated in dose escalation |
| Competitive context | Novo Nordisk’s Ozempic and Wegovy already carry cardiovascular risk reduction indications (semaglutide, GLP-1 only) |
The distinction matters for how the label is marketed. Novo’s semaglutide cardiovascular labels rest on placebo controlled superiority; Lilly chose an active comparator with its own cardiovascular claim, which is a higher bar and a different statistical result. Lilly closed at $1,174.61, effectively flat. Separately, Fierce Pharma’s oral GLP-1 tracker, citing IQVIA data via Citi, put Foundayo at 40,862 US prescriptions in the week ending August 28, its first week above 40,000 and up from 36,620 the prior week, against roughly 175,000 for the Wegovy pill. Those are single source figures and are attributed accordingly.
What did the ESC Congress 2026 Hot Line sessions show for eplontersen, aficamten and milvexian?
Three industry Phase 3 programs presented full data in Munich between August 28 and 29, 2026. Eplontersen missed its ATTR-CM composite with a rate ratio of 0.89 and no added benefit on top of a stabilizer; aficamten confirmed the first positive trial in non obstructive HCM with a 3.0 point KCCQ difference; and milvexian confirmed a null result after acute coronary syndrome with a hazard ratio of 1.05.
| Trial | Drug and sponsors | Population | Primary result | Key detail | Status |
|---|---|---|---|---|---|
| CARDIO-TTRansform (Aug 28) | Eplontersen (Wainua), AstraZeneca and Ionis; antisense TTR silencer, 45 mg SC every four weeks | 1,432 adults with wild type or hereditary ATTR-CM; mean age 72; 57% on a stabilizer at baseline | Composite of CV mortality and recurrent CV events through 140 weeks: rate ratio 0.89 (95% CI 0.73 to 1.09; p=0.277); 381 events in 210 patients vs 392 in 231 | No additional benefit in patients on background stabilizer; nominally significant benefit in the monotherapy subgroup; TTR suppression robust through week 140 (HCPLive on the presentation). BioSpace reports a combination hazard ratio of 1.14 from the presentation and quotes Stifel calling it “clearly worse than expected” | Topline miss disclosed July 9, 2026; Wainua remains approved for ATTR polyneuropathy |
| ACACIA-HCM (Aug 28) | Aficamten, Cytokinetics; cardiac myosin inhibitor, 5 to 20 mg daily by echo guided titration | 517 adults with symptomatic non obstructive HCM outside Japan; 36 week primary analysis | KCCQ-CSS +11.4 vs +8.4 (difference 3.0, p=0.021); peak VO2 +0.64 vs −0.03 mL/kg/min (difference 0.67, p=0.003) | NYHA class improvement 41.9% vs 27.8%; NT-proBNP ratio 0.43 vs 1.00; CV events 8.5% vs 7.7% (p=0.678); LVEF below 50% in 10.5% vs 0.8%; AE discontinuations 7.0% vs 1.9%; serious AEs 20.2% vs 14.7%. Published in NEJM (Masri et al.) | sNDA planned Q4 2026; topline with the same primary numbers was announced May 5, 2026 |
| LIBREXIA ACS (Aug 29) | Milvexian, Bristol Myers Squibb and Johnson & Johnson; oral factor XIa inhibitor, 25 mg twice daily | 14,194 patients within seven days of ACS at 893 sites in 44 countries; median 10 months | CV death, MI or ischemic stroke 5.4% vs 5.1%; HR 1.05 (95% CI 0.91 to 1.21; p=0.50) | BARC 3c or 5 bleeding 0.3% in both arms (HR 1.04). Presented by P. Gabriel Steg; published in NEJM | Stopped for futility November 2025; LIBREXIA AF (100 mg twice daily) and secondary stroke prevention (25 mg twice daily) trials continue with toplines expected in 2026 (Fierce Biotech) |
Why does the eplontersen combination result matter for Alnylam and the TTR market?
CARDIO-TTRansform is the first large trial to show a TTR silencer adding nothing measurable on top of a stabilizer, while Alnylam’s HELIOS-B, presented again at ESC on August 30, 2026, showed vutrisiran reducing all cause mortality and recurrent cardiovascular events by 28.2 percent overall and 32.8 percent in the monotherapy population through 36 months. The two datasets now define the open question in ATTR-CM: whether combination benefit is a class property or a drug property.
| Element | HELIOS-B (vutrisiran, Alnylam) | CARDIO-TTRansform (eplontersen, AZ and Ionis) |
|---|---|---|
| Mechanism | RNAi TTR silencer, subcutaneous every three months | Antisense TTR silencer, subcutaneous every four weeks |
| Enrollment | 654 patients; 259 (40%) on tafamidis at baseline | 1,432 patients; 57% on a stabilizer at baseline |
| Primary outcome | All cause mortality and recurrent CV events reduced 28.2% overall, 32.8% monotherapy, through 36 months (Alnylam ESC release, Aug 30) | CV mortality and recurrent CV events: rate ratio 0.89, not significant; no added benefit in the stabilizer subgroup |
| New ESC analysis | Post hoc: 52% reduction in risk of intrinsic capacity decline vs placebo; pooled 1,402 patient analysis across four Phase 3 studies showed consistent effects by sex | Full presentation by Mathew Maurer (Columbia); TTR knockdown robust through week 140 |
| Aug 28 close | ALNY $237.10, flat on the day after an intraday low of $223.61 | IONS $61.05 (−2.2%); AZN $162.70 (−1.1%) |
Jefferies, quoted by StockTwits, called the eplontersen result “mostly as expected” with a neutral to negative readthrough to Alnylam and kept a Hold rating. Oppenheimer, per BioSpace, raised the possibility of a signal when eplontersen is combined with a stabilizer. Neither company has published a mechanistic explanation for the divergence, and this page does not offer one. Alnylam is also one of the six Midsized Biotech Alliance of America members that Fierce Pharma named as parties to the pricing agreements Bloomberg reported the White House could announce as soon as Monday, August 31; no such announcement had been made as of the evening of Sunday, August 30.
Why did BioNTech and Genentech stop the autogene cevumeran colorectal cancer trial?
BioNTech disclosed on August 28, 2026 that it is terminating BNT122-01, the Phase 2 trial of autogene cevumeran as adjuvant monotherapy in ctDNA positive, surgically resected stage II high risk and stage III colorectal cancer, after the data safety monitoring board “identified a numerical imbalance in overall survival between treatment arms in this specific patient population.” Genentech, the co developer, told Fierce Biotech there were more deaths in the vaccine arm. The trial had crossed a futility boundary in October 2025 and been continued because the data were immature.
The 6-K does not give patient counts or survival figures. BioNTech said the pancreatic cancer program IMcode003, which combines the vaccine with checkpoint inhibition and chemotherapy, continues as planned. The contrast with Merck and Moderna’s INTerpath-001, which met recurrence free and distant metastasis free survival on August 19, 2026 with intismeran given alongside Keytruda in resected melanoma, is design and setting: monotherapy in a microsatellite stable, immunologically cold tumor against combination therapy in an immune responsive one. BioNTech’s US shares closed at $102.08 on August 28, down 8.4 percent from $111.40. No congress placement for INTerpath-001 had been announced as of Sunday evening, August 30.
What is the status of the Boston Scientific cyberattack as of August 30, 2026?
Boston Scientific’s newsroom update, current as of August 30, 2026, now states that the incident identified on August 25 affects “the ability to manufacture products, as well as process and ship customer orders,” extending the disclosed impact from order processing and shipping into production. The company says its confidence in restoration “continues to increase” and that it is “expeditiously working towards partial restoration for the shipping of some products this week,” while the timeline for full restoration is still not known.
| Date | Disclosure | Source |
|---|---|---|
| Aug 25 | Incident identified; certain IT and on premise systems affected | Company statement |
| Aug 26 | Public disclosure; global disruption to order processing and shipping; 8-K; materiality undetermined | Company statement via MedTech Dive; 8-K |
| Aug 28 | Manufacturing operations confirmed disrupted; new remote monitoring communicators cannot be activated; no impact found on implanted cardiac rhythm device function or on existing remote monitoring | Company statement via MedTech Dive |
| Aug 30 | Orders can be taken electronically but not processed or shipped; partial restoration of shipping for some products targeted for the week of Aug 31; full restoration timeline unknown | news.bostonscientific.com update |
The exchange closes were $49.86 on August 25, $48.17 on August 26, $46.67 on August 27 and $46.84 on August 28. The company has not specified the nature of the attack and has not quantified the financial impact. Stryker’s March 2026 cyberattack, which disrupted ordering and shipping for weeks with a material first quarter impact, remains the closest precedent per MedTech Dive.
What are the terms of Teva’s stalking horse bid for BioXcel’s Igalmi?
BioXcel Therapeutics filed for Chapter 11 in the District of Delaware on August 28, 2026 (case 26-11360) with a $19 million debtor in possession facility from its existing secured lenders and a Section 363 asset sale agreement naming Teva as stalking horse bidder. Teva’s release sets the price at $57.5 million in upfront cash plus up to $67.5 million in time based and sales milestones, for up to $125 million, for worldwide rights to BXCL501 (Igalmi, dexmedetomidine sublingual film) in agitation associated with schizophrenia and bipolar disorder.
| Term | Detail (BioXcel and Teva releases, Aug 28, 2026) |
|---|---|
| Court and case | US Bankruptcy Court, District of Delaware, Case No. 26-11360 |
| DIP financing | $19 million from existing secured lenders |
| Stalking horse bid | Teva: $57.5 million upfront; up to $67.5 million in milestones tied to FDA approval timing and sales; up to $125 million total; subject to higher bids and court approval |
| Asset | Worldwide rights to Igalmi and the pending sNDA for at home use, PDUFA target action date November 14, 2026 |
| Operations | Motions filed to continue employee wages and benefits and patient support programs; Igalmi remains available |
| Stock | BTAI closed at $0.18 on August 28; BioSpace reported a decline of more than 70 percent on the day |
This is the second Section 363 auction of a biotech asset in a month, after PTC and Lilly bought Sangamo’s programs for a combined $163.55 million in cash. The Teva bid puts a firm cash number, $57.5 million, on a marketed CNS product with a dated regulatory catalyst eleven weeks out, and leaves the value of that catalyst in the milestone column.
What did Genentech agree with DualityBio and how does it fit the licensing ledger?
DualityBio announced on August 28, 2026 an exclusive worldwide license under which Genentech will develop next generation antibody drug conjugates built on DualityBio’s DUPAC payload platform against oncology targets Genentech selects, for $45 million upfront, more than $1 billion in aggregate development, regulatory and commercial milestones, and tiered royalties on net sales. DualityBio handles discovery and early global clinical work; Genentech takes over from Phase 1a. It is Genentech’s second Asian license in a week after the August 24 Hanmi obesity deal.
| Deal (2026) | Upfront cash | Total potential | Cash share of headline | Stage |
|---|---|---|---|---|
| BioMarin / Alesta | $275M | $490M | ~56% | Near approval |
| Biohaven / SK Biopharmaceuticals (Aug 26) | $400M | $795M | ~50% | Registrational |
| Genentech / Hanmi (Aug 24) | $190M | $2.3B | ~8% | Phase 1 |
| Haisco / Sentivera (Aug 25) | $75.89M cash and equity | $1.5B+ | ~5% | Preclinical |
| Genentech / DualityBio (Aug 28) | $45M | >$1B | ~4% | Platform, preclinical |
| Tolerance Bio / NeoImmuneTech (Aug 19) | Equity, undisclosed | $260M milestones | ~0% cash | Clinical |
The DualityBio terms print at the bottom of the cash share curve the ledger has tracked since August 21: the earlier the biology, the smaller the cash fraction of the headline. DUPAC is described by the company as a set of non topoisomerase payloads designed to address resistance to topoisomerase I inhibitor ADCs, which is the payload class behind Enhertu and Trodelvy. Separately, AusperBio raised a $120 million Series C to take its hepatitis B candidate into Phase 3, per Fierce Biotech.
What did the Fifth Circuit decide in PhRMA’s Medicare negotiation case?
On August 27, 2026 the US Court of Appeals for the Fifth Circuit affirmed the dismissal of PhRMA’s constitutional challenge to the Medicare Drug Price Negotiation Program, according to Fierce Pharma and The Hill. Judge Leslie Southwick wrote that manufacturers lack a protected interest in selling to Medicare beneficiaries at a preferred price because participation in Medicare and Medicaid is voluntary. The panel rejected the due process, separation of powers and Eighth Amendment excessive fines claims brought with the National Infusion Center Association and the Global Colon Cancer Association. PhRMA said it is reviewing the decision and all options.
The ruling lines up with the Third Circuit’s dismissal of Merck’s and AstraZeneca’s constitutional claims and a Maryland federal court’s rejection of AstraZeneca’s bundling challenge. The one live industry path remains the D.C. Circuit’s August 18 remand of Teva’s challenge to the bona fide marketing standard, which is an administrative claim rather than a constitutional one.
Which COVID-19 vaccines did the FDA approve for the 2026 to 2027 season and who is eligible?
On August 27, 2026 the FDA approved updated COVID-19 vaccines matched to the XFG subvariant of the JN.1 lineage: Pfizer and BioNTech’s Comirnaty XFG, Moderna’s Spikevax and mNexspike, and Novavax’s Nuvaxovid, which Sanofi markets. As in 2025, the approvals cover adults 65 and older and younger people with at least one condition that raises the risk of severe COVID-19; the general population indication was not restored. Pfizer said shipping began the same day.
| Vaccine | Manufacturer | Eligible ages (with a high risk condition below 65) |
|---|---|---|
| Comirnaty XFG | Pfizer / BioNTech | 5 to 64 with a condition; all 65+ |
| Spikevax | Moderna | 6 months to 64 with a condition; all 65+ |
| mNexspike | Moderna | 12 to 64 with a condition; all 65+ |
| Nuvaxovid | Novavax, marketed by Sanofi | 12 to 64 with a condition; all 65+ |
Per Pharmacy Times, the FDA treated the XFG change as a strain adaptation requiring only nonclinical and manufacturing data, the same process as prior updates. Medical Daily reports that the CDC’s Advisory Committee on Immunization Practices has lacked a functioning quorum since a court ruling in March and that no meeting date is confirmed, leaving no federal recommendation for the new formula; that account is a single outlet’s and is attributed as such. The same report says AHIP member plans have committed to cover recommended immunizations without cost sharing through the end of 2027.
What else happened in life sciences on August 28 to 30, 2026?
The FDA authorized Abbott’s Libre Duo 10 Day, the first wearable that continuously monitors both glucose and ketones, through the De Novo pathway on August 25 for people two and older with diabetes, with readings every minute and alerts at ketone thresholds. Amylyx closed at $34.74 on August 28, its first close below the $35.50 price of its August 19 offering, with no closing or underwriters’ option announcement on its press release index as of Sunday evening. Capricor closed at $9.59, its first down session after four consecutive gains, with no response to Kaos Capital, no 8-K and no new FDA communication surfaced. Revolution Medicines closed at $207.88, down 6.0 percent, with no company news surfaced. Moderna closed at $137.99.
Frequently asked questions
What is Mimrylo?
Mimrylo is Takeda’s brand name for rusfertide, a once weekly subcutaneous hepcidin mimetic peptide approved by the FDA on August 28, 2026 to treat erythrocytosis in adults with polycythemia vera. It limits iron availability to red blood cell production, reducing the need for phlebotomy.
How effective was rusfertide in the VERIFY trial?
In VERIFY, 76.9 percent of patients on rusfertide plus standard care needed no phlebotomy during weeks 20 to 32, compared with 32.9 percent on placebo plus standard care, in 293 adults who had required frequent phlebotomy despite standard treatment.
How much does Protagonist receive from the Mimrylo approval?
Protagonist said the approval triggers $275 million: $200 million as the second installment of its April 2026 US opt out election and a $75 million approval milestone. It also keeps tiered royalties of 14 to 29 percent on worldwide net sales and up to $875 million in further milestones.
What is Lisraya and who makes it?
Lisraya is brepocitinib, an oral JAK1 and TYK2 inhibitor from Priovant Therapeutics, a Roivant company. The FDA approved it on August 27, 2026 as the first oral and first targeted treatment for dermatomyositis in adults, at 30 mg once daily.
Does Lisraya have a boxed warning?
Yes. Lisraya carries the JAK inhibitor class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis.
What did the FDA approve Mounjaro for on August 28, 2026?
The FDA approved Mounjaro (tirzepatide) to lower the risk of cardiovascular death, non fatal heart attack or non fatal stroke in adults with type 2 diabetes at high risk of those events, based on SURPASS-CVOT, which showed non inferiority to dulaglutide with a hazard ratio of 0.92. Superiority was not established.
Did Mounjaro beat Trulicity on cardiovascular outcomes?
Mounjaro showed an 8 percent lower rate of MACE-3 than Trulicity, but the 95.3 percent confidence interval (0.83 to 1.01) crossed 1.0, so Lilly’s release states that superiority was not established. The approval rests on non inferiority to a comparator with a proven cardiovascular benefit.
What did CARDIO-TTRansform show for eplontersen?
Eplontersen did not significantly reduce the composite of cardiovascular mortality and recurrent cardiovascular events through 140 weeks in 1,432 patients with ATTR-CM (rate ratio 0.89, 95 percent CI 0.73 to 1.09, p=0.277). Patients already on a stabilizer saw no added benefit; patients on eplontersen alone saw a nominally significant benefit.
Does the eplontersen failure affect Alnylam’s Amvuttra?
Amvuttra (vutrisiran) is approved for ATTR-CM on the strength of HELIOS-B, where it reduced all cause mortality and recurrent cardiovascular events by 28.2 percent in a population in which 40 percent were on tafamidis at baseline. The eplontersen data raise the question of whether combination benefit is a class property, but they do not change Amvuttra’s label. Jefferies described the readthrough as neutral to negative.
What did ACACIA-HCM show for aficamten in non obstructive HCM?
Aficamten improved KCCQ-CSS by 3.0 points more than placebo (p=0.021) and peak VO2 by 0.67 mL/kg/min more (p=0.003) at 36 weeks in 517 patients, making ACACIA-HCM the first positive Phase 3 in non obstructive HCM. LVEF fell below 50 percent in 10.5 percent of aficamten patients versus 0.8 percent on placebo. Cytokinetics plans an sNDA in the fourth quarter of 2026.
Why did milvexian fail in LIBREXIA ACS?
In 14,194 patients after acute coronary syndrome, milvexian 25 mg twice daily did not reduce cardiovascular death, MI or ischemic stroke (5.4 percent versus 5.1 percent, hazard ratio 1.05, p=0.50). Severe bleeding was 0.3 percent in both arms. The trial was stopped for futility in November 2025; the atrial fibrillation and secondary stroke prevention trials continue.
Why did BioNTech stop its colorectal cancer vaccine trial?
The data safety monitoring board found a numerical imbalance in overall survival between arms, with more deaths in the vaccine arm, in a Phase 2 trial of autogene cevumeran given alone after surgery in ctDNA positive stage II and III colorectal cancer. BioNTech and Genentech terminated the study on August 28, 2026; the pancreatic combination program continues.
What is Teva paying for BioXcel’s Igalmi?
Teva is the stalking horse bidder in BioXcel’s Chapter 11 case with $57.5 million in upfront cash and up to $67.5 million in milestones, for up to $125 million, for worldwide rights to Igalmi. The bid is subject to higher offers in a Section 363 auction and bankruptcy court approval.
What did Genentech pay DualityBio?
Genentech paid $45 million upfront for an exclusive worldwide license to develop ADCs on DualityBio’s DUPAC payload platform, with more than $1 billion in potential milestones and tiered royalties.
Who can get the updated COVID-19 vaccine in 2026?
The FDA approved the XFG adapted vaccines from Pfizer and BioNTech, Moderna and Novavax for adults 65 and older and for younger people with at least one condition that raises the risk of severe COVID-19, with minimum ages of 6 months (Spikevax), 5 years (Comirnaty) or 12 years (mNexspike, Nuvaxovid). Eligibility and coverage for people outside those groups depend on state pharmacy rules and individual plans in the absence of a current federal recommendation.
Sources
Primary sources. FDA press announcement, “FDA Approves First Drug of Its Kind for Polycythemia Vera,” August 28, 2026. FDA press announcement, “FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults,” August 27, 2026. FDA press announcement, “FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar,” August 25, 2026. Takeda news release, “FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera,” August 28, 2026, and NDA acceptance release, March 2, 2026. Protagonist Therapeutics release on the Mimrylo approval, August 28, 2026, and opt out release, April 28, 2026. Priovant Therapeutics release (GlobeNewswire), August 27, 2026, and NDA acceptance release, March 3, 2026. Eli Lilly investor release, “FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes,” August 28, 2026. Cytokinetics release and NEJM publication (Masri et al.), August 28, 2026; topline release, May 5, 2026. ESC press release, “Milvexian did not reduce cardiovascular events in the LIBREXIA ACS trial,” August 29, 2026. Ionis release, “Update on CARDIO-TTRansform,” July 9, 2026. Alnylam release, ESC Congress 2026 data, August 30, 2026. BioNTech Form 6-K and release, August 28, 2026. Boston Scientific newsroom, “Update on recent cybersecurity incident,” as of August 30, 2026. BioXcel Therapeutics release (GlobeNewswire), August 28, 2026; Teva release, August 28, 2026. DualityBio release (PR Newswire), August 28, 2026. Exchange closes for August 25 to 28, 2026.
Trade and general press (attributed). HCPLive on the CARDIO-TTRansform ESC presentation, August 28, 2026. BioSpace, “‘Worse than expected’ Wainua data muddies water for TTR silencers,” August 28, 2026. StockTwits on the Jefferies note, August 28, 2026. Fierce Biotech on the BioNTech termination and on Teva’s stalking horse bid, August 28, 2026. Fierce Pharma on the Mounjaro approval, the oral GLP-1 tracker and the Fifth Circuit PhRMA ruling, August 27 to 28, 2026. The Hill on the Fifth Circuit ruling, August 27, 2026. BioSpace on the BioXcel filing, the DualityBio deal and the Mounjaro approval, August 28, 2026. MedTech Dive on Boston Scientific, August 28, 2026. Pharmacy Times and Medical Daily on the COVID-19 vaccine approvals, August 27 to 28, 2026. TCTMD on ACACIA-HCM.
Related coverage
- Boston Scientific’s cyberattack, Tezspire’s EoE Phase 3 win, and the week’s catalyst dates going 0 for 4 (August 28, 2026)
- Rasonque’s pancreatic cancer approval and Biohaven’s up to $795M opakalim deal, with the cash share rate card (August 27, 2026)
- Sentivera’s $1.5B Haisco license and the biotech IPO window (August 26, 2026)
- Capricor’s November 22 PDUFA date and Roche’s up to $2.3B Hanmi obesity license (August 25, 2026)
- The binary ledger: Amylyx’s $500.2M offering and the Ultragenyx and Regeneron approvals (August 21, 2026)
- PTC and Lilly bought Sangamo for parts: the $163.55M bankruptcy auction (August 2026)
- Retatrutide vs CagriSema: why 2026 is the year of the triple agonist
